# Donafenib for Recurrent Cervical Cancer

> **NCT05310331** · PHASE2 · UNKNOWN · sponsor: **Lei Li** · enrollment: 20 (estimated)

## Conditions studied

- Targeted Therapy
- Chemotherapy
- Recurrent Cervical Carcinoma
- Metastatic Cervical Carcinoma
- Persistent Advanced Cervical Carcinoma
- Survival Outcomes
- Adverse Effect

## Interventions

- **COMBINATION_PRODUCT:** Donafenib combined with paclitaxel and platinum ± PD-1 antibody

## Key facts

- **NCT ID:** NCT05310331
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-27
- **Primary completion:** 2023-12-27
- **Final completion:** 2024-06-27
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05310331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05310331, "Donafenib for Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05310331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*